{
  "id": 21149546,
  "title": "Amphastar CFO William Peters sells $329,890 in stock",
  "url": "https://urgent.news/2026/11/22/amphastar-cfo-william-peters-sells-329-890-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-22T00:16:03.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/amphastar-cfo-william-peters-sells-329890-in-stock-93CH-5043651"
  },
  "original_language": "en",
  "account": "Amphastar Pharmaceuticals CFO William Peters disposed of a substantial $329,890 worth of the company's common stock on November 16, 2026. This sale, executed under a pre-approved Rule 10b5-1 plan adopted in March 2026, involved the sale of 11,000 shares at a price of $29.99 per share, slightly above the prevailing market price of $28.25. The transaction was conducted after a remarkable six-month increase in share value, which soared over 53%. Notably, Peters also made a counterbalancing move by purchasing 11,000 shares through employee stock options, acquiring them at an exercise price of $17.99 per share, which amounted to $197,889. These shares were fully vested and could be exercised immediately. Consequently, Peters' ownership in Amphastar Pharmaceuticals now stands at 167,076 shares. For those seeking a more in-depth analysis of AMPH's valuation and the actions of its executives, the InvestingPro Pro Research Report provides comprehensive insights into this and over 1,400 other US equities. Meanwhile, Amphastar Pharmaceuticals reported impressive figures in their Q3 2026 financial results, with revenue reaching $207.6 million, surpassing market expectations. The company's adjusted earnings per share came in at $1.14, outperforming the anticipated $0.86 by 32.6%. This success was largely attributed to the strong performance of key products BAQSIMI and Primatene MIST, both of which recorded record sales for the quarter. However, Amphastar faced a slight hiccup as its gross margin declined to 48% from 51% in the same period last year, a decrease driven by pricing pressures and remediation costs at its IMS manufacturing facility. Despite this, the board approved an additional $50 million for share repurchases, demonstrating confidence in the company's financial health. The company's revenue growth was substantial, up 8% from the previous year and 13% from the previous quarter, reflecting robust commercial execution. The introduction of newer products like ipratropium bromide and teriparatide also played a significant role in driving revenue growth. These developments highlight Amphastar's resilience in navigating operational challenges while achieving notable sales milestones. This account is generated from AI-assisted research and reviewed by an editor.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}